Motesanib plus Carboplatin/Paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Novello, S Scagliotti, G Sydorenko, O Vynnychenko, I Volovat, C Schneider, C McCoy, S Hei, Y Spigel, D
Novello, S
Scagliotti, G
Sydorenko, O
Vynnychenko, I
Volovat, C
Schneider, C
McCoy, S
Hei, Y
Spigel, D
Citations
Altmetric:
Abstract
The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). Treatment and enrollment of patients with squamous histology were permanently discontinued following higher early mortality and gross hemoptysis in those with squamous NSCLC who received motesanib. Enrollment of patients with nonsquamous histology was temporarily halted, but resumed following a protocol amendment (Scagliotti et al. J Clin Oncol. 2012;30:2829-2836). Herein, we report data from the squamous cohort.
Description
Date
2014-08
Publisher
Collections
Keywords
Type
Article
Citation
Motesanib plus Carboplatin/Paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. 2014, 9 (8):1154-61 J Thorac Oncol